top of page

Pharmacology & Disease Models

At Alpha Genesis, our pharmacology and disease model capabilities support the development of novel therapeutics through scientifically validated, translational in vivo systems. We offer a comprehensive suite of immunological, inflammatory, metabolic, and genetic disease models designed to accelerate discovery and optimize efficacy in preclinical pipelines. With deep expertise in biomarker validation and gene/cell therapy testing, our team delivers reliable, reproducible data to guide drug development from early-stage screening through IND-enabling studies.

Immunopharmacology & Immunotoxicology

We conduct detailed immune profiling to assess cytokine responses, vaccine adjuvanticity, and immunotoxic effects, supporting preclinical safety and mechanism-of-action studies.

Inflammatory & Metabolism Models

Our models of chronic inflammation, obesity, insulin resistance, and NASH reflect human pathophysiology and enable translational evaluation of candidate therapeutics.

Gene & Cell Therapy Models​​

We support gene and cell therapy programs with advanced delivery platforms (AAV, LNP, viral vectors) to assess tropism, persistence, immunogenicity, and tissue-specific expression.

Discovery Pharmacology

We offer exploratory pharmacology studies to evaluate target engagement, dose-response relationships, and preliminary efficacy in behaviorally and biologically relevant systems.

Biomarker Discovery & Validation

We identify and validate fluid and tissue biomarkers through serial sampling, flow cytometry, histopathology, and multiplex immunoassays to support translational development.

Autoimmune/Rare Disease Indications

We develop and apply preclinical models for autoimmune and orphan indications, enabling immunologic and functional characterization of novel therapies in clinically relevant systems.

Automated Pipetting System
bottom of page